<DOC>
	<DOCNO>NCT01835353</DOCNO>
	<brief_summary>This prospective , multi-center , non-randomized , control study 2 sequential group P2Y12 inhibitor-naive consecutive STEMI patient undergo primary PCI . Following aspirin 325 mg LD , patient receive 60 mg 100 mg prasugrel , respectively . Platelet reactivity ( PR ) assess Hour 0 ( prasugrel 's administration immediately prior PCI ) Hours 0.5 , 1 , 2 , 4 thereafter . Platelet function test ( PRU ) perform VerifyNow ( Accumetrics Inc. , San Diego , CA , USA ) P2Y12 function assay .</brief_summary>
	<brief_title>High ( 100mg ) Versus Standard ( 60mg ) Loading Dose Prasugrel Patients With ST-elevation Myocardial Infarction ( STEMI ) , Undergoing Primary Percutaneous Coronary Intervention ( PCI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>ST elevation myocardial infarction Pain onset &lt; 12 hour Age &gt; 18 &lt; 75 year Written inform consent history stroke/transient ischemic attack oral anticoagulation hemodynamic instability platelet count &lt; 100000/Î¼L hematocrit &lt; 30 % creatinine clearance &lt; 30 ml/min severe hepatic dysfunction active bleeding weight &lt; 60 Kg periprocedural IIb/IIIa inhibitor administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>prasugrel</keyword>
	<keyword>ST elevation myocardial infarction</keyword>
</DOC>